Archive · 17 Sep 2026
PB Fintech Growth Hinges on Regulatory Clarity and Execution
PB Fintech helps people buy insurance and offers other financial services.
Two brokerages studied how the company may grow.
Bernstein believes new rules about insurance commissions will probably not seriously hurt the business.
It expects the rules to focus especially on products sold through banks.
Macquarie says Policybazaar is gaining a larger share of business from many insurers.
General insurance and health insurance were important growth areas in FY26.
The company is also developing businesses such as payments, healthcare, pensions and reinsurance.
Macquarie believes these gains could help PB Fintech grow earnings and profit margins.
Bernstein expects proposed insurance commission rules to be resolved with limited impact on PB Fintech.
Macquarie says PB Fintech increased its share of insurers’ broker commission pool to 6% in FY26 from 4% in FY25.
General insurance revenue rose 50% to Rs 2,786 crore in FY26, while standalone health insurance revenue increased 43% to Rs 1,245 crore.
Standalone health remained PB Fintech’s strongest franchise, with its commission-pool share rising to 20% from 16%.
Macquarie retained an Outperform rating and a Rs 1,950 12-month target price for PB Fintech.
- Who
- PB Fintech, including its Policybazaar business, and brokerages Bernstein and Macquarie.
- What
- Brokerages offered differing assessments of PB Fintech’s regulatory risks, market-share gains and growth prospects.
- When
- The assessments concern FY26 performance and the company’s prospects through FY28; Macquarie’s report was dated September 2026.
- Where
- The business operates primarily in India, with Macquarie also citing a UAE business.
- Why
- The outlook depends on the final insurance commission regulations, continued gains within insurer channels and execution of new businesses.
Regulatory Relief and Limited Impact
Execution and Market-Share Growth
Main near-term issue
Regulatory Relief and Limited Impact
Bernstein sees insurance commission regulations as the key overhang but expects the final framework to avoid deep cuts.
Execution and Market-Share Growth
Macquarie focuses less on the regulatory question and more on PB Fintech’s increasing share within insurers’ broker channels.
Primary growth explanation
Regulatory Relief and Limited Impact
Bernstein believes the company’s underlying economics, long-term growth and margin expansion can remain intact if commission reductions are measured.
Execution and Market-Share Growth
Macquarie attributes growth to gains across general insurance, standalone health and life-insurer channels rather than merely favorable sector conditions.
Future potential
Regulatory Relief and Limited Impact
Bernstein expects regulatory clarity to remove uncertainty and support a recovery in PB Fintech and potentially life-insurer stocks.
Execution and Market-Share Growth
Macquarie sees additional options in the UAE business, PB Healthcare, PB Pay, PB Money, Pensionbazaar, PB for Business, reinsurance and Paisabazaar’s expansion.
- Macquarie rating
- Outperform
- Macquarie target price
- Rs 1,950 over 12 months
- Insurance commission-pool share
- 6% in FY26, up from 4% in FY25
- FY26 insurance-linked revenue
- Rs 5,811 crore, up 41% year over year
- Largest FY26 segment
- General insurance, contributing 48% of insurance-linked revenue
- Standalone health share
- 20% of the commission pool in FY26, up from 16%
- Expected earnings growth
- Macquarie forecasts approximately 58% EPS CAGR between FY26 and FY28